Results showed that DSS increased the expression of gene il18 (1.9-fold), which was associated with IBD pathways, while GML pretreatment reversed the increase of il18 (2.6-fold, Fig. 2J, Fig. S3C, and Table S1). The gene discussed is GML; the disease is inflammatory bowel disease.